Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-26-111286
Filing Date
2026-03-17
Accepted
2026-03-17 17:37:40
Documents
1
Period of Report
2026-03-14

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7788
  Complete submission text file 0001193125-26-111286.txt   9255
Mailing Address BAARERSTRASSE 14 ZUG Switzerland
Business Address BAARERSTRASSE 14 ZUG Switzerland 6173154600
CRISPR Therapeutics AG (Issuer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127
Business Address
Patel Naimish (Reporting) CIK: 0002021679 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37923 | Film No.: 26763729